Endpoints at JPM26: Biopharma's Foundational Reset

Lock in your JPM plans with Endpoints

JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
VIRTUAL + SAN FRANCISCO

With JPM just three days away, one question is top of mind in San Francisco: What actually works when funding is tight, and the old playbook no longer applies?

Join Endpoints at the center of the action — in-person or virtually (free). On Monday and Tuesday, we’re bringing together the leaders shaping biopharma’s future for real conversations — no pitches, no fluff.

Need a place to get things done? The Endpoints Hub is your premium coworking lounge — a quiet space to take meetings, compare notes with people who get it, and figure out your next move over breakfast, lunch, and meaningful conversation.

GET YOUR VIRTUAL PASS

Free virtual programming will run from 8 AM - 12 PM PT each day.

Charting biotech's course for 2026

Catalent CEO Alessandro Maselli and John Carroll return for their annual predictions session, charting what's ahead for biotech in 2026. Last year, Carroll took heat for his bullish M&A forecast — until the second half proved him right with a string of blockbuster deals. This year, they're tackling everything from manufacturing pressures to funding dynamics and what the dealmaking momentum really means for the months ahead.

Agenda highlight

Few scientists have shaped modern immunology like Fred Ramsdell. The newly minted Nobel laureate — now a scientific advisor at Sonoma Biotherapeutics — helped uncover the biology behind immune tolerance, laying the groundwork for today’s cell and gene therapies. Ramsdell joins Endpoints’ Lei Lei Wu to discuss how biotech and basic science move forward — together.